Palmitoylation of -catenin is critical to synapse plasticity and memory formation. We found that -catenin palmitoylation is also instrumental in the development of neuropathic pain. The abundances of palmitoylated -catenin and the palmitoyl acyltransferase DHHC3 were increased in dorsal root ganglion (DRG) sensory neurons in rat models of neuropathic pain. Inhibiting palmitoyl acyltransferases or decreasing -catenin abundance in the DRG by intrathecal injection of 2-bromopalmitate or shRNA, respectively, alleviated oxaliplatin or nerve injury-induced neuropathic pain in the rats. The palmitoylation of -catenin, which was induced by the inflammatory cytokine TNF-, facilitated its interaction with the voltage-gated sodium channel Na v 1.6 and the kinesin motor protein KIF3A, which promoted the trafficking of Na v 1.6 to the plasma membrane in DRG neurons and contributed to mechanical hypersensitivity and allodynia in rats. These findings suggest that a palmitoylation-mediated KIF3A/-catenin/Na v 1.6 complex enhances the transmission of mechanical and nociceptive signals; thus, blocking this mechanism may be therapeutic in patients with neuropathic pain.
INTRODUCTION
Sorting and transportation of intracellular proteins to specific subcellular compartments are highly regulated precise processes, which serve as two of the essential methods to regulate the neuron and brain function in physiological and pathological scenarios. Palmitoylation is a reversible attachment of a 16-carbon acyl chain to cysteine residues through a thioesteric bond, which may enhance the hydrophobicity of targeting proteins and its affinity with intracellular lipid organelles, thus modifying the sorting and trafficking, as well as the function, of intracellular proteins (1, 2) . Studies have demonstrated that protein palmitoylation is critically involved in the modulation of neuronal functions during neurodevelopment and in neuropsychiatric disease (3, 4) . -Catenin, a component of the cadherin-catenin cell adhesion complex, is highly expressed in the brain and contributes to cognitive function. Marked deficits in learning and memory are observed in mice with -catenin mutations (5, 6) , and palmitoylation of -catenin mediates activity-induced synaptic plasticity in central neurons (7) . In mammalian cells, palmitoylation is catalyzed by a family of palmitoyl acyltransferases (PATs), each containing a conserved Asp-His-HisCys (DHHC) motif (8) . PATs are highly expressed in neurons (9, 10) and are, like -catenin, involved in the modulation of neuronal function. For example, the PAT DHHC5 interacts with the scaffolding protein postsynaptic density-95 (PSD-95), which has a critical role in learning and memory (11) , and genetic variation in the gene encoding the PAT DHHC8 is involved in the pathogenesis of schizophrenia (12) . Furthermore, the hyperexcitability of sensory neurons contributes to chronic pain (13) . However, whether and how palmitoylation of -catenin, through its regulation of dorsal root ganglion (DRG) neuronal activity, participates in chronic pain is unclear.
Voltage-gated sodium (Na v ) channels mediate the rising phase of action potentials and remarkably regulate the excitability and firing pattern in central and peripheral neurons. To date, nine isoforms of the  subunit (Na v 1.1 to Na v 1.9) have been identified (14) . Among them, Na v 1.6 is widely expressed in neurons in the DRG (15) and contributes to the propagation and generation of action potentials (16) . Results obtained from knockout and antisense studies support a pivotal role for Na v 1.6 in the development of neuropathic pain (17, 18) . It is recognized that several Na v isoforms, including Na v 1.6, are mainly localized in the cytoplasm of primary sensory neurons and modulation of the sorting and trafficking of intracellular Na v s may significantly modify channel function and neuronal excitability (19) . Among several known factors, kinesin superfamily motor proteins play a critical role in regulating the intracellular trafficking, transport, and localization of Na v s in afferent fibers (19) . Kinesin superfamily proteins (KIFs), which contain 15 members [kinesin 1 (KIF1) to KIF14B], mediate the microtubule-dependent transport of cargo proteins in various cell types (20) . Previous studies showed that overexpression of KIF5B increased the cell surface and axonal distribution of Na v 1.8, and knockdown of KIF5B decreased the current density of Na v 1.8 in DRG neurons, indicating that the anterograde axonal transport of Na v 1.8 occurs through a mechanism involving motor protein (21) . In addition, the expression of mutant KIF3A blocked vesicle transport from the rough endoplasmic reticulum (ER) to the Golgi apparatus in cultured Xenopus cells (22) . Notably, reports suggest that palmitoylation of the N-methyl-d-aspartate (NMDA) acid glutamate receptor subunit NR2B in central neurons participates in various physiological contexts, such as cognition and chronic pain (23, 24) . Here, we investigated the role of palmitoylation of -catenin and its potential interaction with motor proteins KIFs in Na v 1.6 membrane trafficking and their functional significance in the pathogenesis of chronic pain.
progressive reduction in the hindpaw withdrawal threshold in rats (fig. S1A). By considering the critical role of palmitoylation of -catenin in synaptic plasticity and memory formation (7), we then examined the palmitoylation of -catenin in spinal dorsal horn and DRG tissues after oxaliplatin treatment using the acyl-biotin exchange (ABE) assay. -Catenin palmitoylation in DRG tissues, but not the spinal dorsal horn, was significantly increased after oxaliplatin treatment (Fig. 1, A and B), which coincided with the time course of mechanical hypersensitivity induced by oxaliplatin. Meanwhile, suppression of -catenin palmitoylation by consecutive intrathecal injection of broad-spectrum palmitoylation inhibitor 2-bromopalmitate (2-BP; fig. S1B) significantly reduced mechanical allodynia induced by oxaliplatin (Fig. 1C) . Notably, we also showed that lumbar 5 ventral root transection (L5-VRT), a rodent model of neuropathic pain induced by nerve injury, significantly increased the abundance of palmitoylated -catenin in the DRG, but not the spinal dorsal horn (Fig. 1, D and E) , and the application of 2-BP significantly ameliorated the L5-VRT-induced mechanical allodynia (Fig. 1F) . Furthermore, the recombinant adeno-associated virus (AAV) encoding -catenin short hairpin RNA (shRNA) (pAAV-CAG-eGFP-U6-shRNA) was intrathecally injected into the subarachnoid space of L4 to L6 spinal cord of rats. Twenty-one days after virus injection, marked green fluorescence in DRG neurons suggested a high efficiency of transfection ( fig. S1C ). The analysis of polymerase chain reaction (PCR) and Western blotting results indicated that the expression of mRNA encoding -catenin ( fig. S1D ) and the abundance of -catenin protein (fig. S1E) in the DRG were significantly reduced on day 21 after -catenin shRNA injection. Knockdown of -catenin in the DRG significantly attenuated the mechanical allodynia induced by oxaliplatin (Fig. 1G ) or L5-VRT (Fig. 1H) . Furthermore, we examined the distribution of -catenin in DRG. Immunostaining study revealed the expression of -catenin in calcitonin gene-related peptide-positive; isolectin B4 (IB4)-positive, small-diameter; and neurofilament 200-positive, large-diameter DRG neurons (Fig. 1I) . Collectively, these results demonstrated the critical role of palmitoylation of -catenin in DRG neurons in the induction of neuropathic pain induced by oxaliplatin or nerve injury.
The inflammatory cytokine tumor necrosis factor- (TNF-) has played an extensive role in the development and maintenance of neuropathic pain (26) . Here, we observed the increased abundance of TNF- in the DRG in the rats that received oxaliplatin injection ( Fig. 2A) or L5-VRT (Fig. 2B ), which exhibited a time course similar to that of the increase in mechanical hypersensitivity and -catenin palmitoylation in these rodents. Notably, intraperitoneal injection of thalidomide, an inhibitor of TNF- synthesis, blocked the increase in oxaliplatin-induced -catenin palmitoylation (Fig. 2C) . Meanwhile, incubation of isolated, cultured DRG neurons with TNF- significantly enhanced the palmitoylation of -catenin (Fig. 2D) . These results suggest the potential role of TNF- signaling in the increased -catenin palmitoylation in DRG neurons in the setting of neuropathic pain.
DHHC3 played a critical role in palmitoylation of -catenin
In mammalian cells, palmitoylation is catalyzed by a family of PATs, each containing a conserved DHHC motif. Here, we examined the mRNA expression of all PATs in DRG in rodent models of neuropathic pain. The results showed that the expression of mRNA encoding DHHC3, DHHC8, and DHHC9 was significantly increased in the DRG of rats that received oxaliplatin treatment or L5-VRT (Fig. 3A) . To define which DHHC palmitoylates -catenin in chronic pain, we then performed co-immunoprecipitation (Co-IP) with -catenin antibody to determine the potential interaction between -catenin and DHHCs in the DRG. The results showed that the potential binding of -catenin with DHHC3, but not DHHC8 or DHHC9, was increased after oxaliplatin treatment (Fig. 3B) . Consistently, increased content of -catenin was recovered in the immunocomplex precipitated by DHHC3 antibody (Fig. 3C ), which suggests a potential interaction between -catenin and DHHC3 in the DRG lysates from the rats injected with oxaliplatin. We also observed a significantly increased abundance of DHHC3, with a similar time-dependent increase as seen for the palmitoylation of -catenin, in the DRG of rats injected with oxaliplatin (Fig. 3D) . In addition, high-resolution images from structured illumination microscopy (SIM) suggested that DHHC3 can colocalize with the -catenin in DRG neurons and that the colocalization significantly increased 10 days after oxaliplatin treatment ( Fig. 3E and movie S1 ). Intrathecal injection of DHHC3 shRNA, which decreased the mRNA and protein expression of DHHC3 ( fig. S2, A and B) , significantly inhibited -catenin palmitoylation in the DRG and mechanical allodynia induced by oxaliplatin treatment or L5-VRT (Fig. 3, F to I) . Furthermore, incubation with TNF- significantly increased the abundance of DHHC3 (Fig. 3J ) and its colocalization with -catenin (Fig. 3K ) in cultured DRG neurons. These results demonstrated that the palmitoylation of -catenin by DHHC3 in DRG played a critical role in the development of neuropathic pain induced by oxaliplatin or nerve injury.
Palmitoylation of -catenin mediated the membrane trafficking of Na v 1.6 Palmitoylation serves as one of the posttranslational modification to increase protein hydrophobicity and facilitate protein interactions with lipid bilayers, thereby substantially altering the sorting and function of proteins (2) . To identify the underlying mechanism by which palmitoylated -catenin mediated the chronic pain, we examined the potential interactions between -catenin and Na v channels in the DRG (namely Na v 1.6, Na v 1.7, Na v 1.8, and Na v 1.9) using the Co-IP method. We found that -catenin antibody pulled down a substantial amount of Na v 1.6 and Na v 1.7 but barely any Na v 1.8 or Na v 1.9 (Fig. 4A ). This potential interaction between -catenin and Na v 1.6, but not Na v 1.7, was significantly attenuated by intrathecal injection of broad-spectrum palmitoylation inhibitor 2-BP (Fig. 4A) . Immunostaining revealed that -catenin colocalized with Na v 1.6 in DRG tissues (Fig. 1I) , and highresolution imaging demonstrated an enhanced colocalization in response to oxaliplatin, which was significantly attenuated by intrathecal injection of broad-spectrum palmitoylation inhibitor 2-BP (Fig. 4B) . Furthermore, we observed increased membrane and total abundance of Na v 1.6 in DRG in the rats injected with oxaliplatin ( Fig. 4C) , which exhibited a similar time-dependent increase as that of -catenin palmitoylation and mechanical allodynia. Note that the proportion of Na v 1.6 trafficking to the membrane was increased in the DRG of rats injected with oxaliplatin (Fig. 4C) . To verify the role of membranelocalized Na v 1.6 in the chronic pain, we intrathecally injected Na v 1.6 shRNA, which induced marked green fluorescence in DRG neurons ( fig. S3A ) and decreased abundance of Na v 1.6 mRNA ( fig. S3B ) and protein ( fig. S3C ) 21 days later. Intrathecal injection of Na v 1.6 shRNA reduced the surface accumulation of Na v 1.6 10 days after oxaliplatin treatment (Fig. 4D ) and significantly attenuated oxaliplatin-or L5-VRT-induced mechanical allodynia (Fig. 4, E and F) . Next, we further examined whether membrane trafficking of the Na v 1.6 isoform in the DRG-mediated chronic pain by applying the reagent brefeldin A (BFA), which generally blocks protein transport from the ER to the Golgi apparatus, thus inhibiting membrane-directed trafficking of intracellular proteins (27) . The results showed that consecutive intrathecal injection of BFA (15 nmol/10 l) inhibited the surface accumulation of Na v 1.6 10 days after oxaliplatin treatment (Fig. 4G ). Note that 2-BP ( Fig. 5A ), as well as -catenin shRNA (by intrathecal injection) (Fig. 5B) , attenuated the surface accumulation of Na v 1.6 and the proportion of Na v 1.6 trafficking but did not change the total expression of Na v 1.6 in DRG neurons 10 days after oxaliplatin treatment. Intrathecal injection of 2-BP (Fig. 5C ) or -catenin shRNA (Fig. 5D ) also decreased the surface accumulation of Na v 1.6 in DRG neurons 15 days after L5-VRT. Consistently, incubation with TNF- significantly increased the membrane accumulation of Na v 1.6 in cultured DRG neurons (Fig. 5E) . Notably, preincubation of 2-BP significantly disrupted the colocalization of Na v 1.6 with -catenin ( Fig. 5F ) and inhibited the membrane accumulation of Na v 1.6 ( Fig. 5E ) in cultured DRG neurons incubated with TNF-. These results suggest a critical role of palmitoylated -catenin in the membrane trafficking of Na v 1.6 in DRG neurons in the setting of neuropathic pain.
We further defined the modulation of Na v 1.6 isoform function by palmitoylated -catenin in human embryonic kidney (HEK) 293T cells transfected with Na v 1.6. Incubation with TNF- significantly increased the palmitoylation of -catenin ( Fig. 6A ) and current density of Na v 1.6 (meaning that the enhanced membrane accumulation led to the increase of Na v 1.6 channel currents) (Fig. 6 , B and C) in transfected HEK293T cells, which was attenuated by pretreatment with 2-BP (Fig. 6 , A to C). Neither TNF- nor 2-BP altered the activity or recovery characteristics of Na v 1.6 channels in the transfected HEK293T cells (Fig. 6 , D to F). Next, we transfected the plenti-CMVCtnnd2-mCherry-3FLAG into the Na v 1.6-contained HEK293T cells, which was validated by the immunoblotting results that transfection of plenti-CMV-Ctnnd2-mCherry-3FLAG significantly increased -catenin abundance ( fig. S4 ). It was observed that palmitoylated -catenin abundance ( Fig. 6G) and Na v 1.6 current density (Fig. 6H) were also increased in HEK293T cells that overexpressed -catenin, but these increases were prevented by incubation with 2-BP (Fig. 6 , H and I). These results further confirmed the significance of palmitoylated -catenin to modulate the function of Na v 1.6 isoform.
KIF3A was involved in palmitoylated -catenin-mediated membrane trafficking of Na v 1.6 A previous report showed that motor protein kinesins played an important role in neuronal cargo trafficking (20) . To determine whether motor protein kinesins contributed to palmitoylated -catenin-mediated Na v 1.6 trafficking, we first examined the interaction between -catenin and several motor proteins by Co-IP. The results showed that -catenin showed a potent potential interaction with KIF3A and KIF3B whereas -catenin barely potential interacted with KIF5A, KIF5B, KIF17, and KIFC2 precipitated by -catenin antibody in DRG (Fig. 7A) . In addition, consecutive intrathecal injection of 2-BP significantly inhibited the formation of immunocomplex containing -catenin and KIF3A, but not KIF3b, in DRG of the rats injected with oxaliplatin (Fig. 7A) . Similarly, oxaliplatin markedly increased the contents of -catenin in the immunocomplex precipitated by KIF3A antibody in the DRG, and this was also significantly attenuated by intrathecal injection of 2-BP (Fig. 7B) . High-resolution imaging further confirmed that the colocalization of -catenin and KIF3A was significantly increased in DRG neurons from oxaliplatin-treated rats compared with those from vehicle-treated rats, and this was blocked by intrathecal injection of 2-BP (Fig. 7C) . Consistently, in the cultured DRG neurons, incubation with TNF- significantly increased the colocalization of -catenin and KIF3A in the cytoplasm of cultured DRG neurons, which was also prevented by preincubation with 2-BP (Fig. 7D) . These results suggested that palmitoylated -catenin can function potentially as an adaptor protein for KIF3A in DRG neurons in the setting of neuropathic pain.
Next, we explored whether KIF3A participated in palmitoylated -catenin-mediated Na v 1.6 trafficking and contributed to the chronic pain. Co-IP results showed that the potential interaction between KIF3A and Na v 1.6 was enhanced in the DRG after oxaliplatin treatment, which was abolished by intrathecal injection of 2-BP (Fig. 7E) or -catenin shRNA (Fig. 7F) . SIM also showed that 2-BP or -catenin shRNA prevented the oxaliplatin-induced colocalization of KIF3A and Na v 1.6 in DRG neurons (Fig. 7G) . In addition, SIM study also showed that incubation with TNF- increased the colocalization of KIF3A and Na v 1.6 in cultured DRG neurons, and this was inhibited by 2-BP (Fig. 7H) . These results suggest that -catenin palmitoylation is a critical modification to promote interaction (direct or indirect, unclear) between KIF3A and Na v 1.6 in the DRG of rats with neuropathic pain.
We further found that intrathecal injection of KIF3A shRNA, knocking down the expression of KIF3A in DRG ( fig. S5 ), significantly prevented oxaliplatin-induced surface accumulation of Na v 1.6 in DRG neurons (Fig. 7I) and exhibition of mechanical allodyniaassociated behavior in rats (Fig. 7K) ; intrathecal injection of KIF3A shRNA also prevented these effects of L5-VRT (Fig. 7, J and L) . Western DHHC1  DHHC2  DHHC3  DHHC4  DHHC5  DHHC6  DHHC7  DHHC8  DHHC9  DHHC11  DHHC12  DHHC13  DHHC14  DHHC15  DHHC16  DHHC17  DHHC18  DHHC19  DHHC20  DHHC21 One-way ANOVA followed by Tukey post hoc test, **P < 0.01 versus the vehicle group. (E) High-resolution image from structured illumination microscopy (SIM) assessing the colocalization between -catenin and DHHC3 in DRG tissues of rats treated with vehicle or oxaliplatin (day 10). n = 4 rats per group. Two-tailed, independent Student's t test, **P < 0.01 versus the vehicle group. White box, zoomed right. Scale bar, 1 m. (F) -Catenin palmitoylation in DRG tissues from rats treated with oxaliplatin (day 10) after intrathecal injection of DHHC3 shRNA. n = 5 rats per group. One-way ANOVA followed by Tukey post hoc test, **P < 0.01 versus vehicle and ## P < 0.01 versus the corresponding scramble + oxaliplatin group. (G) -Catenin palmitoylation in DRG tissues from L5-VRT rats (day 15) after intrathecal injection of DHHC3 shRNA. n = 5 rats per group. One-way ANOVA followed by Tukey post hoc test, **P < 0.01 versus the sham group and ## P < 0.01 versus the corresponding scramble + L5-VRT group. (H and I) Mechanical allodynia induced by oxaliplatin treatment (H) or L5-VRT (I) after intrathecal injection of DHHC3 shRNA. n = 12 rats in per group. Two-way repeated-measures ANOVA followed by Bonferroni post hoc test, F 3,176 = 463.2 (H), F 3,132 = 349.4 (I), P < 0.0001. **P < 0.01 versus the control group and ## P < 0.01 versus the corresponding oxaliplatin or L5-VRT group. (J) Representative blots and histogram assessing DHHC3 abundance in cultured DRG cells cultured with TNF- (1 ng/ml for 4 hours). n = 7 per group. Two-tailed, independent Student's t test, **P < 0.01 versus vehicle. (K) High-resolution image assessing the colocalization between DHHC3 and -catenin in cultured DRG neurons incubated with vehicle or TNF- (1 ng/ml for 4 hours). White box, zoomed right. n = 3 per group. Two-tailed, independent Student's t test, **P < 0.01 versus the vehicle group. Scale bar, 1 m.
blotting analysis also showed that KIF3A shRNA inhibited the increased surface expression of Na v 1.6 induced by TNF- in cultured DRG neurons (Fig. 7M) and ameliorated the increase of Na v 1.6 current density induced by TNF- in HEK293T cells (Fig. 7N) . These results suggested the critical role of motor protein KIF3A in -catenin palmitoylation-mediated Na v 1.6 surface accumulation in the setting of neuropathic pain.
Palmitoylation mediated the formation of a complex comprising KIF3A, Na v 1.6, and -catenin By considering the enhanced potential interaction among -catenin, KIF3A, and Na v 1.6 in DRG neurons in the rats with neuropathic pain, we performed three-color fluorescent staining to DRG neurons. Highresolution images revealed that the colocalization of KIF3A, Na v 1.6, and -catenin was increased in DRG neurons 10 days after oxaliplatin (A) Co-IP of Na v 1.6, Na v 1.7, Na v 1.8, and Na v 1.9 with antibody to -catenin in lysates from DRG tissues isolated from rats treated with vehicle, oxaliplatin (day 10), or 2-BP + oxaliplatin (day 10). n = 6 rats per group. (B) High-resolution image showing the colocalization between Na v 1.6 and -catenin in DRG tissues from rats treated with vehicle, oxaliplatin (day 10), or 2-BP + oxaliplatin (day 10). n = 4 rats per group. Oneway ANOVA followed by Tukey post hoc test, **P < 0.01 versus the vehicle group and ## P < 0.01 versus the corresponding oxaliplatin group. Scale bar, 1 m. (C) Abundance of membrane and total Na v 1.6 in DRG tissues from vehicle or oxaliplatin rats and the proportion of Na v 1.6 trafficking in vehicle or oxaliplatin rat's DRG tissues. n = 6 rats per time point. One-way ANOVA followed by Tukey post hoc test, *P < 0.05, **P < 0.01 versus the vehicle group. TfR, transferrin receptor. (D) Surface expression of Na v 1.6 induced by oxaliplatin (day 10) after intrathecal injection of Na v 1.6 shRNA. n = 6 rats per group. One-way ANOVA followed by Tukey post hoc test, **P < 0.01 versus the vehicle group; # P < 0.05, ## P < 0.01 versus the corresponding oxaliplatin group. (E and F) Mechanical allodynia induced by oxaliplatin (E) and L5-VRT (F) after intrathecal injection of Na v 1.6 shRNA. n = 12 rats per group. Two-way repeated-measures ANOVA followed by Bonferroni post hoc test, F 3,176 = 343.8 (E), F 3, 132 = 392.8 (F), P < 0.0001. **P < 0.01 versus the corresponding control group and ## P < 0.01 versus the corresponding oxaliplatin or L5-VRT group. (G) Surface accumulation of Na v 1.6 in DRG tissues of oxaliplatin (day 10) rats after intrathecal injection of brefeldin A (BFA) (15 nmol/10 l). n = 6 rats per group. One-way ANOVA followed by Tukey post hoc test, **P < 0.01 versus the vehicle group and ## P < 0.01 versus the corresponding oxaliplatin group.
treatment (Fig. 8A ) or in cultured DRG neurons incubated with TNF- ( Fig. 8B and movie S2), and this colocalization was significantly reduced by intrathecal injection or preincubation with 2-BP (Fig. 8,  A and B) . These results suggest that palmitoylation of -catenin was a critical step for the interaction of KIF3A, Na v 1.6, and -catenin and subsequent Na v 1.6 membrane trafficking in response to mechanical sensation.
DISCUSSION
The trafficking of Na v 1.6 toward plasma membrane is an essential step for its function to mediate the neuronal excitability and repetitive firing, thereby critically involved in the development of neurological disorders including chronic pain (17) . Previous studies reported that knockdown of Na v 1.6 expression in sensory neurons substantially attenuated the DRG neuronal excitability and mechanical allodynia in the rodent models of chronic pain induced by local inflammation (17) or nerve injury (18) . It was also reported that in vitro exposure to oxaliplatin induced remarkable after-potentials in the A-fiber compound action potential response to electrical stimulation at 30°C in human and mouse myelinated axons, which was absent in Na v 1.6 knockout mice (28) . Our findings in this study confirmed the critical role of membrane-directed trafficking of Na v 1.6 in sensory neurons and its induction by inflammation in the development of mechanical hypersensitivity in rodent models of neuropathic pain. Our data further uncovered a mechanism that enhances Na v 1.6 abundance at the membrane, namely through protein-protein interactions promoted by the palmitoylation of -catenin. -Catenin is a neuronspecific catenin that functions as a bridge between cadherins and PDZ-containing scaffolding proteins, thus substantially regulating the physiological process of learning and memory (5) . For example, -catenin binds to the -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR)-binding protein and glutamate receptor interaction protein and promotes the insertion of AMPAR subunit 2 (GluA2) in hippocampal synapses (29) . Palmitoylation regulates the sorting and trafficking of intracellular proteins including ligand-or voltagegated ion channels [such as the NMDA receptor (30) , AMPAR (31) , and Na v 1.2 (32)] in neurons. Here, we found that increased palmitoylation of -catenin in DRG neurons promoted membranedirected trafficking of the Na v 1.6 isoform in the DRG and oxaliplatin-or L5-VRT-induced mechanical allodynia in rats. Considering the potential that the drugs dispersed to both the DRG and spinal cord after intrathecal injection, the present study cannot exclude the possibility that the anti-allodynia effect of intrathecal delivery of the -catenin shRNA or the PAT inhibitor 2-BP might partially result from Membrane, total Na v 1.6 expression, and proportion of Na v 1.6 trafficking in oxaliplatin (on day 10) rat DRG tissues after 2-BP (A) or -catenin shRNA (B) intrathecal application. n = 5 rats per group. One-way ANOVA followed by Tukey post hoc test, **P < 0.01 versus the vehicle group and ## P < 0.01 versus the corresponding oxaliplatin group. (C and D) Abundance of Na v 1.6 in membrane of L5-VRT (day 15) rat DRG tissues after intrathecal application of 2-BP (C) or -catenin shRNA (D). n = 5 rats per group. One-way ANOVA followed by Tukey post hoc test, **P < 0.01 versus the sham group and ## P < 0.01 versus the corresponding L5-VRT group.
(E) Abundance of Na v 1.6 in membrane of DRG neurons after incubation of vehicle, TNF- (1 ng/ml for 4 hours) or 2-BP (100 nM) 20 to 30 min before TNF-. n = 6 per group. One-way ANOVA followed by Tukey post hoc test, **P < 0.01 versus the vehicle group and ## P < 0.01 versus the TNF- group. (F) Highresolution images showing the colocalization between Na v 1.6 and -catenin in cultured DRG neurons described in (E). n = 4 per group. One-way ANOVA followed by Tukey post hoc test, **P < 0.01 versus the vehicle group and ## P < 0.01 versus the TNF- group. Scale bar, 1 m.
drug action in the spinal dorsal horn, but we, nonetheless, demonstrated their effect to modulate Na v 1.6 membrane trafficking and current density in DRG neurons. TNF-, a proinflammatory cytokine critically involved in the pathogenesis of neuropathic pain (26, 33) , was an inducing signal, enhanced by oxaliplatin, to promote increased abundance of the palmitoylase DHHC3 and its interaction/colocalization with -catenin in DRG sensory neurons and mechanical allodynia in rats. Hence, these results established that palmitoylation of -catenin, potentially by DHHC3, prompted the membrane-directed trafficking of Na v 1.6 in sensory neurons and contributed to the development of neuropathic pain. Our data also suggest a critical role for the motor protein KIF3A in this mechanism. Previous studies demonstrated that various motor proteins of the KIFs exhibit differential function to form intracellular cargo apparatus and regulate protein trafficking, including that of the vascular endothelial growth factor receptor 2 in endothelial cells (34) , the glutamate receptor in the ventral nerve cord of Caenorhabditis elegans (worms) (35) , and voltage-gated potassium (K v ) channels in mouse hippocampal neurons (36) . Specifically, KIF3A mediates the polarized trafficking of K v 1.2 channel to axons (37, 38) and the transport of vesicles containing -catenin toward the plasma membrane in the developing neuroepithelium (39) . Through both direct and indirect association, kinesins also promote the polarized trafficking of cytoplasmic p120 catenin along microtubules toward their plus ends (40) . Here, triple-fluorescence SIM analysis demonstrated substantial colocalization of KIF3A, Na v 1.6, and -catenin in DRG neurons from rats treated with oxaliplatin and was blocked by the palmitoylation inhibitor 2-BP. These data suggest an interaction of -catenin, KIF3A, . n = 6 rats per group. (C) SIM triple-fluorescence staining of -catenin and KIF3A in DRG tissues from rats treated as described in (A). n = 3 rats per group. One-way ANOVA followed by Tukey post hoc test, **P < 0.01 versus the vehicle group and ## P < 0.01 versus the corresponding oxaliplatin group. Scale bar, 1 m. (D) Colocalization of -catenin and KIF3A in cultured DRG neurons after incubation with vehicle, TNF- (1 ng/ml for 4 hours), or 2-BP (100 nM) 20 to 30 min before TNF-. n = 4 per group. One-way ANOVA followed by Tukey post hoc test, **P < 0.01 versus the vehicle group and ## P < 0.01 versus the corresponding TNF- group. Scale bar, 1 m. (E and F) Co-IP analysis of KIF3A and Na v 1.6 in DRG tissue lysates from oxaliplatin-treated rats (on day 10) after intrathecal application of 2-BP (E) or -catenin shRNA (F). n = 6 rats per group. (G) SIM triple-fluorescence staining of Na v 1.6 and KIF3A in DRG tissues from rats treated as described in (E) and (F). n = 4 rats per group. One-way ANOVA followed by Tukey post hoc test, **P < 0.01 versus the vehicle group and ## P < 0.01 versus the corresponding oxaliplatin group. Scale bar, 1 m. (H) SIM triple-fluorescence staining of KIF3A and Na v 1.6 in cultured neurons after incubation with vehicle, TNF- (1 ng/ml for 4 hours), or 2-BP (100 nM) 20 to 30 min before TNF-. n = 4 per group. One-way ANOVA followed by Tukey post hoc test, **P < 0.01 versus the vehicle group and ## P < 0.01 versus the corresponding TNF- group. Scale bar, 1 m. (I and J) Abundance of surface Na v 1.6 in DRG tissues intrathecally injected with KIF3A shRNA and treated with oxaliplatin (day 10) (I) or subjected to L5-VRT (day 15) (J). n = 5 rats per group. One-way ANOVA followed by Tukey post hoc test, **P < 0.01 versus the corresponding control group and ## P < 0.01 versus the corresponding oxaliplatin or L5-VRT group. (K and L) Mechanical allodynia in rats induced by oxaliplatin (K) or L5-VRT (L) after intrathecal injection of KIF3A shRNA. n = 12 rats per group. Two-way repeated-measures ANOVA followed by Bonferroni post hoc test, F 3,176 = 346.3 (K), F 3,132 = 251.6 (L), P < 0.0001. **P < 0.01 versus the corresponding control group and ## P < 0.01 versus the corresponding oxaliplatin or L5-VRT group. (M) Surface abundance of Na v 1.6 in cultured DRG neurons transfected with KIF3A shRNA and incubated with TNF- (1 ng/ml for 4 hours). n = 5 per group. One-way ANOVA followed by Tukey post hoc test, **P < 0.01 versus the vehicle group and ## P < 0.01 versus the corresponding TNF- group. (N) Na v 1.6 current density in HEK293T cells transfected with KIF3A shRNA and incubated with TNF- (1 ng/ml for 4 hours). n = 10 cells per group. One-way ANOVA followed by Tukey post hoc test, **P < 0.01 versus the scramble group and ## P < 0.01 versus the corresponding TNF- group.
and Na v 1.6 that is driven by (presumably -catenin's) palmitoylation to promote the trafficking of Na v 1.6 to the membrane in sensory neurons. However, the assays used do not prove direct protein interaction; thus, palmitoylated -catenin, KIF3A, and Na v 1.6 may interact indirectly through another protein(s). Further work will certainly refine this mechanism that we propose underlies the hyperexcitability of sensory neurons and mechanical hypersensitivity in rats and whether this mechanism is relevant to pain signaling in humans. The findings reveal molecular targets to explore for the treatment of patients with neuropathic pain.
MATERIALS AND METHODS

Animals
Male Sprague-Dawley rats, weighing 200 to 220 g, were obtained from the Institute of Experimental Animals of Sun Yat-sen University. All animals were housed in separated cages, and the room was kept at 24°C temperature and 50 to 60% humidity under a 12:12-hour light/dark cycle and with ad libitum access to food and water. All experimental procedures were approved by the Local Animal Care Committee and were carried out in accordance with the guidelines of the National Institutes of Health (NIH) on animal care and the ethical guidelines.
Reagents and L5-VRT
Antibodies for all methods are listed in table S3. Oxaliplatin (SigmaAldrich) was freshly diluted with 5% glucose/H 2 O as a stock solution of 1 mg/ml and intraperitoneally injected for five consecutive days to induced mechanical allodynia for rats. The L5-VRT model was performed as described previously (41, 42) . Briefly, surgery was performed on rats under deep anesthesia after intraperitoneal administration of sodium pentobarbital (50 mg/kg) (Sigma-Aldrich). An L5 hemilaminectomy was performed to expose the L5 nerve root. The ventral root was gently pulled out with fine forceps and transected 2 to 3 mm proximal to the DRG, and a small portion (2 mm) of the root was dissected. In the sham group, an identical operation was performed for exposure of the L5 ventral root, but the nerve was not transected.
Drug administration and behavioral test
Intrathecal injection of 2-BP (10 l; SigmaAldrich) was performed according to our previously described method (25) . Briefly, a polyethylene-10 catheter (Smiths) was inserted into the rat's subarachnoid space through L5 to L6 spinal cord segmental intervertebral space, and the tip of the catheter was located at the L5 spinal segmental level. 2-BP was intrathecally injected 30 min before the first dose of oxaliplatin or L5-VRT surgery once per day. The 50% withdrawal threshold was assessed using von Frey hairs (Ugo Basile) as described previously (43) . Briefly, each animal was loosely restrained in a plastic box on a metal mesh and allowed to acclimate for at least 15 min per day for three consecutive days. On the first testing day, the animals were reintroduced to the testing environment and allowed to accommodate, and then series of von Frey filaments with different bending force were presented alternately from the underneath to the mid-plantar surface of each hind paw. In the absence of a paw withdrawal response to the initially selected hair, a stronger stimulus was presented; in the event of paw withdrawal, the next weaker stimulus was chosen. Optimal threshold calculation by this method requires six responses in the immediate vicinity of the 50% threshold. A nociceptive response was defined as a brisk paw withdrawal or flinching of the paw after von Frey filament application. All the experiments were performed by investigators that were blinded to the treatments/conditions.
Injection of AAV
pAAV-CAG-eGFP-U6-shRNA(Ctnnd2), pAAV-CAG-eGFP-U6-shRNA(Zdhhc3), pAAV-CAG-eGFP-U6-shRNA(Scn8a), pAAV-CAGeGFP-U6-shRNA(Kif3a), and pAAV-CAG-eGFP-U6-MCS(NC) were intrathecally injected according to our previously described method (44) . Twenty-one days after the virus injection, the experiments were performed.
shRNA preparation and screening Targeted shRNAs were applied to knock down the abundance of Na v 1.6, DHHC3, KIF3A, and -catenin. Briefly, shRNAs (three each) targeting rat Na v 1.6, DHHC3, KIF3A, or -catenin mRNA were designed and behavioral tests, two-way repeated-measures ANOVA, followed by Bonferroni post hoc test, was carried out. Threshold for statistical significance was P < 0.05. Although no power analysis was performed, the sample size was determined according to previous publications in pain-associated behavior and molecular studies.
SUPPLEMENTARY MATERIALS
www.sciencesignaling.org/cgi/content/full/11/523/eaar4394/DC1 Fig. S1 . shRNA knockdown of -catenin in DRG tissues. Fig. S2 . shRNA knockdown of DHHC3 in DRG tissues. Fig. S3 . shRNA knockdown of Nav1.6 in DRG tissues. Fig. S4 . Overexpression of -catenin in HEK293T cells. Fig. S5 . shRNA knockdown of KIF3a in DRG tissues. Table S1 . shRNA nucleotide sequences. Table S2 . PCR primer sequences. Table S3 . Antibodies. Movie S1. Colocalization between -catenin and DHHC3 in oxaliplatin-treated DRG neurons. Movie S2. Colocalization among -catenin, KIF3A and Nav1.6 in DRG neurons incubated with TNF-.
